Acquisitions, Study Results, Product Enhancements, and New Appointments - Research Report on Astex, Boston Scientific, WellCare, ResMed, and Immunomedics

NEW YORK, September 10, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Astex Pharmaceuticals Inc. (NASDAQ: ASTX), Boston Scientific Corporation (NYSE: BSX), WellCare Health Plans, Inc. (NYSE: WCG), ResMed Inc. (NYSE: RMD), and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Astex Pharmaceuticals Inc. Research Report

On September 5, 2013, Astex Pharmaceuticals Inc. (Astex) and Otsuka Pharmaceutical Co. Ltd. (Otsuka) announced that the duos have received approval from the Boards of Directors of their respective companies, for an all-share acquisition deal. As per the arrangement between the two companies, Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash, which represents a 48% premium to the average closing stock price for the previous 30 day period. According to the Company, the purchase price of the deal represents a fully diluted equity value of c.$886 million, calculated using the treasury stock method. According to Astex, the acquisition of the Company would add to Otsuka's existing discovery capabilities and pipeline of therapeutic products for neuroscience, cardiovascular, and oncology indications, and besides providing Otsuka with PYRAMID, the drug discovery platform developed by Astex. Otsuka expects the transaction to close early in Q4 2013, subject to customary closing conditions. The Full Research Report on Astex Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-05/ASTX]

--

Boston Scientific Corporation Research Report

On September 4, 2013, Boston Scientific Corporation (Boston Scientific) announced that The Journal of Allergy and Clinical Immunology, the official scientific journal of the American Academy of Allergy, Asthma & Immunology (AAAAI) published data from Asthma Intervention Research 2 (AIR2) clinical trial, which examines the safety and effectiveness of the Boston Scientific Alair Bronchial Thermoplasty (BT) System. According to the Company, the key findings of the 5 year study on BT-treated patients revealed reduction in the percentage of patients experiencing severe exacerbations (compared to patients treated with sham control); 48%YoY average decrease observed in the rate of severe exacerbations in patients; 88% YoY average decrease observed in the rate of emergency room (ER) visits for respiratory symptoms. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-05/BSX]

--

WellCare Health Plans, Inc. Research Report

On September 5, 2013, WellCare Health Plans, Inc. (WellCare) announced that it has agreed to acquire Windsor Health Group. According to WellCare, members and policy holders will not experience any changes with regards to their plan benefits and coverage as a result of the acquisition. The Company expects the acquisition to close within the next three or four months, subject to customary regulatory approvals, and the transaction is expected to be accretive to its 2014 net income. Alec Cunningham, CEO of WellCare, said, "Windsor's focus on lower income Medicare beneficiaries and those who are dually eligible for Medicare and Medicaid is an excellent fit with WellCare's Medicare and broader government health care programs strategy." He added, "We will work closely with Windsor Health Group to help ensure a smooth transition for members." The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-05/WCG]

--

ResMed Inc. Research Report

On September 3, 2013, ResMed Inc. (ResMed) announced the launch of the Swift FX Nano, a new nasal mask for use with positive airway pressure, (PAP) therapy. According to the Company, the Swift FX Nano nasal mask has a new proprietary design that keeps the mask small and unobtrusive without the need for rigid frames or forehead support, making it a mask that more closely resembles a nasal pillows mask but carriers the seal and performance of a nasal mask. ResMed informed that the mask, which is easy to fit, wear and maintain, represents a significant breakthrough for the nasal mask category, and is now available throughout the United States. Jon Yerbury, ResMed's Vice President, Sleep-Disordered Breathing, said, "By combining the headgear design of a nasal pillows mask with the superior seal of a nasal mask we have created something for patients who want an effective mask that takes up less space." The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-05/RMD]

--

Immunomedics Inc. Research Report  

On September 3, 2013, Immunomedics, Inc. (Immunomedics) announced the appointment of Peter P. Pfreundschuh as Vice President, Finance and CFO of the Company. According to Immunomedics, Mr. Pfreundschuh will succeed Gerard G. Gorman, who will retire from the Company following a transition period. Commenting on the appointment, Cynthia L. Sullivan, President and CEO of Immunomedics, said, "We welcome Peter and look forward to his contributions as a member of our management team as we continue to advance our clinical programs, explore additional strategic collaborations, consider other capital-raising opportunities, and continue to build a successful organization." The Company also informed that Mr. Gorman will continue to serve as a consultant to Immunomedics during the transition period. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-05/IMMU]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports